A Phase Ib/II Open Label Umbrella Study Evaluating Immunotherapy Based Combinations with Metastatic Pancreas Adenocarcinoma.

This study is a open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma

This study is done to determine and evaluate the efficacy of combination therapy with immune checkpoint blockade and chemotherapy used in the perioperative period in eradicating micrometastatic disease. Additionally, the study  compares paired tissue and serum samples (pre-treatment and post-treatment) from individually treated patients to explore the immune effects of combination therapy and predictors of response.

An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

This purpose of this study is to evaluate the safety and tolerability of study drug atezolizumab when administered with bevacizumab and FOLFOX in patients with gastric cancer. This study will also evaluate the safety and tolerability of atezolizumab administered with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

The purpose of this study is to find out which doses of the study drug are safe to give to patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors. The study drug is RO6958688. RO6958688 is an antibody that targets CEA on the tumor cells and may activate the immune system in targeting cancer cells. The study will also explore how the study drug works in the body and on the tumor. The study also wants to find out if RO6958688 can slow down the growth of tumors or stop the cancer.

Quality of Life in Pancreatic Disease

Clinical Setting

5 years post pancreatic surgery.

Study Description

This is a prospective study on patients that have undergone pancreatic surgery for any cause.

The purpose of this research is to better understand the impact of pancreatic surgery on patients’ quality of life with regard to pain, diabetes, diet and need for further interventions after pancreatic surgery. To achieve this, patients will be given questionnaires specifically designed for this purpose.

Safety of auto-transfusion during Pancreatic Surgery

Clinical Setting

Scheduled surgery for pancreatic cancer

Study Description

This is a prospective study to ultimately assess the safety of transfusing patients their own blood during pancreatic cancer surgery if transfusion is necessary. The question being studied at this point is the number of pancreatic tumor cells circulating in patients’ blood at the time of surgery, and comparing with the blood lost at surgery.

Harmonic Motion Imaging of Resected Pancreas Specimens

Clinical Setting

Scheduled surgery for pancreatic cancer

Study Description

This is a prospective study to evaluate a new kind of ultrasound device to measure the tissue in the pancreas and pancreatic cancer. The measurement will be done after surgery is performed on the part of pancreas that has been removed. After this, the specimen is sent to a special laboratory to conduct the unique ultrasound measurement. After the measurement is performed, the specimen will be transferred back to the pathologist who will analyze the specimen in the usual fashion.

CAM Registry: A Registry of Complementary/Alternative Medicine (CAM) Services (Intended for Correlation with Cancer Clinical Symptoms)

Clinical Setting

Patients with pancreas or other GI or Thoracic cancer who are receiving complementary or alternative treatments (CAM) through the Integrative Therapy Program.

Study Description

The Integrative Therapy Program at Columbia University provides multiple services to patients with cancer who are receiving treatment at Columbia University. These treatments include the provision of nutrition counseling, acupuncture treatments, aromatherapy, reiki, reflexology, meditation, yoga and massage therapy to patients in active treatment and survivors.